Personalized oncology without compromise: MCGI celebrates a decade of hope
Article | April 29, 2026
Ten years ago, a bold idea took root in Maine: Geography should never determine the quality of cancer care.
That where you live should not limit your access to the most advanced tools in modern oncology. That precision medicine, powered by genomics, research, and collaboration, should be available for patients who live far beyond major academic medical centers.
From the beginning, MCGI set out to solve a fundamental problem: genomic medicine was advancing rapidly, but access to it was not. Cancer genomics generates extraordinarily complex data. Expertise to interpret that data is most often concentrated in large academic centers. And education for clinicians, counselors, and care teams is either overwhelming, inaccessible, or impractical within already overburdened schedules.
MCGI was built as a precision oncology program grounded in community, powered by science, and designed for real-world care.
Care without compromise, close to home
Precision oncology faces multiple barriers —genomic data is extraordinarily complex, clinical expertise is unevenly distributed, and educational resources that evolve quickly can be overwhelming or simply inaccessible to care teams with limited time and resources.
MCGI aimed to change that for Mainers. And, having helped more than 3,000 cancer patients since 2016, it has.
“One of the ways that I like to think about the MCGI is that it’s truly the rising tide that lifts all boats,” said Jens Rueter, JAX chief medical officer; medical director, Maine Cancer Genomics Initiative.
The first barrier was access. Advanced genomic testing, the foundation of precision oncology, was initially tied to large academic centers, requiring patients to travel long distances and navigate complex systems. With philanthropic funding from the Harold Alfond Foundation and JAX’s advanced understanding of genetics and genomics, MCGI lowered that barrier. Patients across Maine could access advanced genomic testing close to home—without leaving their communities, families, or familiar care teams behind.
One of the ways that I like to think about the MCGI is that it’s truly the rising tide that lifts all boats.
Jens Rueter, M.D., JAX Chief Medical Officer; MCGI Medical Director
Genomic insights are powerful. But insight isn’t impact unless it reaches treatment. MCGI closes that gap, and makes genomics actionable. Genomic reports are dense, technical, and constantly evolving. Interpreting results, identifying relevant therapies, and matching patients to clinical trials is an unrealistic burden for most community oncologists operating under time constraints and heavy caseloads.
Clinicians in the network can submit their patient cases to MCGI’s Genomic Tumor Boards for live, multidisciplinary review. Each case is evaluated by rotating specialists matched to the cancer type such as neuro-oncologists, molecular pathologists, clinical research coordinators, genetic counselors, and other disease-specific experts. These experts translate complex genomic data into clear, actionable treatment options.
What was once inaccessible expertise becomes part of everyday community care.
Empowering care teams
The MCGI model is built around the fact that a cancer patient does not go through treatment alone. MCGI invests deeply in education for everyone involved in the cancer journey, from clinicians and genetic counselors to care givers and patients themselves. Through its integration with the JAX Cancer Center, MCGI creates patient-facing resources that demystify genomics and help families engage in informed conversations with their doctors, whether in Maine or beyond.
In partnership with JAX Genomic Education, MCGI is also working to help build the future workforce of precision oncology. New training programs and collaborative courses are reaching previously overlooked professional groups, including genetic counselors and allied health professionals—expanding the ecosystem of expertise needed to sustain personalized care at scale.
At its core, MCGI operates as a bridge linking together healthcare, research, and community partners. Researchers help shape clinical decisions. Clinicians help inform future research priorities. And every patient case contributes to a growing body of knowledge that fuels better tools, smarter workflows, and more relevant cancer research.
It’s an ecosystem built on care.
Looking forward
As MCGI looks ahead to its next decade, the vision is clear: expand access, empower more care teams, and bring this model to more places. For patients and families, that means more resources, more knowledge, and more confidence navigating precision medicine. For clinicians, it means deeper support, real-time collaboration, and continued learning.
How to get involved
Patients and Families:
Explore patient resources and learn how to talk to your doctor about precision oncology by clicking here.
Clinicians:
Submit a case or seek to attend at Genomic Tumor Board by clicking here.
Access JAX’s genomic education resources by clicking here.
Support MCGI:
MCGI is made possible by bold philanthropic investment from The Harold Alfond Foundation. Support for MCGI enables us to build on that investment and extend the benefits of this program to cancer patients all around the country. Help us bring personalized cancer care close to every home.
Diagnosed with stage four prostate cancer, Henry Grandgent expected a future of long hospital drives and distant specialists. Instead, the Maine Cancer Genomics Initiative (MCGI) brought world-class cancer care to his island community.
